Key result
Iloprost inhibits ex vivo platelet aggregation in healthy volunteers but causes minor post-infusion rebound hyperaggregability.
Why the study?
Does Iloprost infusion inhibit platelet aggregation in healthy volunteers?
Population
6 healthy volunteers
Design
Other
Follow-up
2 hours after termination of infusion
Authors
Loading...
Iloprost may inhibit platelet aggregation ex vivo in volunteers; leaves open clinical antithrombotic utility and rebound risks.
Does Iloprost infusion inhibit platelet aggregation in healthy volunteers?
Iloprost infusion effectively inhibits platelet aggregation in healthy volunteers without significant clinical side effects, though minor rebound hyperaggregability is observed post-infusion.
Yardumian et al. (2009) studied Healthy volunteers (n=6). ZK 36374 (Iloprost) was evaluated on ex vivo platelet aggregation responses to ADP and collagen. ZK 36374 (Iloprost) infusion (0.5-2 ng/kg/min) in 6 healthy volunteers significantly inhibited ex vivo platelet aggregation to ADP and collagen, with minor rebound hyperaggregability post-infusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: